<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738045</url>
  </required_header>
  <id_info>
    <org_study_id>REC-H-PhBSU-21001</org_study_id>
    <nct_id>NCT04738045</nct_id>
  </id_info>
  <brief_title>Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients</brief_title>
  <official_title>Comparative Therapeutic Efficacy and Safety of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ahmed Essam</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>October 6 University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison outcomes of a large cohort of moderate and severe COVID-19 patients received&#xD;
      remdesivir alone with patients who received remdesivir in combination with lopinavir/&#xD;
      ritonavir in addition to standard management.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim of the study&#xD;
&#xD;
        1. To assess the difference in patients' clinical status improvement between patients&#xD;
           receiving remdesivir alone and patients receiving remdesivir and lopinavir/ ritonavir.&#xD;
&#xD;
        2. To detect time to improvement in oxygenation among both groups.&#xD;
&#xD;
        3. To detect duration of hospitalization and mortality rate in both groups.&#xD;
&#xD;
        4. To detect incidence and duration of mechanical ventilation in both treatment arms.&#xD;
&#xD;
        5. To monitor of adverse events of both drugs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 1, 2020</start_date>
  <completion_date type="Anticipated">February 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of cured patients in the interventional group versus the proportion of cured patients in the control group</measure>
    <time_frame>&quot;through study completion, an average of 3 months&quot;</time_frame>
    <description>Clinical cure will be assessed after 5-7 days from starting treatment based on:&#xD;
Improvement in oxygenation (SpO2/FiO2 ratio).&#xD;
Time to improvement in oxygenation.&#xD;
Duration of hospitalization.&#xD;
Mortality rate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monitoring of adverse events.</measure>
    <time_frame>&quot;through study completion, an average of 3 months&quot;</time_frame>
    <description>The occurrence of adverse events will be recorded on a daily basis, with a focus on: bacterial or fungal infections, elevation of AST or ALT level &gt; 3x the upper limit of normal range.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily.</description>
    <arm_group_label>control</arm_group_label>
    <other_name>control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lopinavir/ Ritonavir and Remdesivir combination</intervention_name>
    <description>Remdesivir will be administrated intravenously (IV) at a dose of 200 mg loading dose then 100 mg once daily and Lopinavir / ritonavir at a dose of 400 /100 once daily for 5 days</description>
    <arm_group_label>interventional</arm_group_label>
    <other_name>intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Hospitalized adult patients with pneumonia evidenced by chest CT scan.&#xD;
&#xD;
          -  Laboratory (RT-PCR) confirmed infection with 2019-nCoV or strongly suspected to be&#xD;
             infected with SARS-COV2 with confirmation studies pending.&#xD;
&#xD;
          -  And at least one of the following:&#xD;
&#xD;
               1. Respiratory frequency ≥30/min.&#xD;
&#xD;
               2. Blood oxygen saturation ≤93% on room air (RA).&#xD;
&#xD;
               3. Partial pressure of arterial oxygen to fraction of inspired oxygen ratio&#xD;
                  (PaO2/FiO2) &lt;300.&#xD;
&#xD;
               4. Worsening of lung involvement, defined as an increase in number and/or extension&#xD;
                  of pulmonary areas of consolidation, need for increased FiO2 to maintain stable&#xD;
                  O2 saturation, or worsening O2 saturation of &gt;3% with stable FiO2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Baseline elevation of alanine aminotransferase (ALT) or aspartate aminotransferase&#xD;
             (AST) levels &gt; 5-fold the upper limit of the normal range.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Known hypersensitivity to drugs or any component of the formulation.&#xD;
&#xD;
          -  Serious co-morbidity, including: Hepatic patients child Pugh class C.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rania M Sarhan, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beni-Suef University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beni-suef University</name>
      <address>
        <city>Banī Suwayf</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>October 6 University</investigator_affiliation>
    <investigator_full_name>Ahmed Essam</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>Remdesivir</keyword>
  <keyword>Lopinavir/ Ritonavir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Lopinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

